SuperworthMaze Therapeutics EPS MAZE
Diluted earnings per share by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jun 30, 2026
- −$2.52
- Latest quarter, Q2 FY26
- −$0.76
- Fiscal year 2025
- −$3.23
Maze Therapeutics' earnings per share was −$2.52 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.76.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.23 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.76 | n/a | −$2.52 | |
| Q1 FY26 | −$0.45 | n/a | −$2.53 | |
| Q4 FY25 | −$0.65 | n/a | −$3.23 | |
| Q3 FY25 | −$0.66 | n/a | n/a | |
| Q2 FY25 | −$0.77 | −124% | n/a | |
| Q1 FY25 | −$1.15 | n/a | n/a | |
| Q3 FY24 | −$10.25 | n/a | n/a | |
| Q2 FY24 | $3.22 | n/a | n/a | |
| Q1 FY24 | −$13.91 | n/a | n/a |
Against its peers
Companies in Biotechnology nearest Maze Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MAZEMaze Therapeutics | −$2.52 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| MGTXMeiraGTx | $0.71 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| Peer median | $0.94 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Maze Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.